{
  "objCls" : "Guideline",
  "@id" : "https://www.pharmgkb.org/data/guideline/PA166104995",
  "@context" : "https://www.pharmgkb.org/jsonld/guideline.jsonld",
  "id" : "PA166104995",
  "name" : "Dutch Pharmacogenetics Working Group Guideline for metoprolol and CYP2D6",
  "relatedChemicals" : [ {
    "objCls" : "Chemical",
    "@id" : "https://www.pharmgkb.org/data/chemical/PA450480",
    "@context" : "https://www.pharmgkb.org/jsonld/chemical.jsonld",
    "id" : "PA450480",
    "name" : "metoprolol"
  } ],
  "relatedGenes" : [ {
    "objCls" : "Gene",
    "@id" : "https://www.pharmgkb.org/data/gene/PA128",
    "@context" : "https://www.pharmgkb.org/jsonld/gene.jsonld",
    "id" : "PA128",
    "symbol" : "CYP2D6",
    "name" : "cytochrome P450, family 2, subfamily D, polypeptide 6"
  } ],
  "source" : "DPWG",
  "summaryHtml" : "<p>Select another drug or reduce dose of metoprolol for CYP2D6 poor and intermediate metabolizer patients. Use a dose titration of metoprolol for CYP2D6 ultra metabolizers or select an alternative drug. </p>",
  "textHtml" : "<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for metoprolol based on CYP2D6 genotype [Article:<a href=\"/pmid/21412232\">21412232</a>].  They recommend either selecting another drug or dose reduction for poor and intermediate metabolizer patients, with dose titration for ultra metabolizers.</p><table class=\"table table-striped table-condensed table-hover table-bordered\"><tr><th> Phenotype (Genotype) </th><th> Therapeutic Dose Recommendation </th><th> Level of Evidence </th><th> Clinical Relevance </th></tr><tr><td> PM (2 inactive alleles) </td><td> Heart failure: select alternative drug (e.g., bisoprolol, carvedilol) or reduce dose by 75%.  Other indications: be alert to ADEs (e.g., bradycardia, cold extremities) or select alternative drug (e.g., atenolol, bisoprolol). </td><td> Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints. </td><td> Clinical effect (S): long-standing discomfort (48-168 hr) without permanent injury e.g. failure of therapy with tricyclic antidepressants, atypical antipsychotic drugs; extrapyramidal side effects; parkinsonism; ADE resulting from increased bioavailability of tricyclic antidepressants, metoprolol, propafenone (central effects e.g. dizziness); INR 4.5-6.0; neutropenia 1.0-1.5x10^9/l; leucopenia 2.0-3.0x10^9/l; thrombocytopenia 50-75x10^9/l.  </td></tr><tr><td> IM (2 decreased activity alleles, or 1 active and 1 inactive allele, or 1 decreased activity and 1 inactive allele) </td><td> Heart failure: select alternative drug (e.g., bisoprolol, carvedilol) or reduce dose by 50%.  Other indications: be alert to ADEs (e.g., bradycardia, cold extremities) or select alternative drug (e.g., atenolol, bisoprolol).   </td><td> Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints. </td><td> Clinical effect (S): short-lived discomfort (&lt; 48 hr) without permanent injury: e.g. reduced decrease in resting heart rate; reduction in exercise tachycardia; decreased pain relief from oxycodone; ADE resulting from increased bioavailability of atomoxetine (decreased appetite, insomnia, sleep disturbance etc); neutropenia &gt; 1.5x10^9/l; leucopenia &gt; 3.0x10^9/l; thrombocytopenia  &gt; 75x10^9/l; moderate diarrhea not affecting daily activities; reduced glucose increase following oral glucose tolerance test. </td></tr><tr><td> UM (gene duplication in absence of inactive or decreased activity alleles) </td><td> Heart failure: select alternative drug (e.g., bisoprolol, carvedilol) or titrate dose to a maximum of 250% of the normal dose in response to efficacy and ADE.  Other indications: select alternative drug (e.g., atenolol, bisoprolol) or titrate dose to a maximum of 250% of the normal dose in response to efficacy and ADE.    </td><td> Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints. </td><td> Clinical effect (S): long-standing discomfort (&gt; 168 hr), permanent symptom or invalidating injury e.g. failure of prophylaxis of atrial fibrillation; venous thromboembolism; decreased effect of clopidogrel on inhibition of platelet aggregation; ADE resulting from increased bioavailability of phenytoin; INR &gt; 6.0; neutropenia 0.5-1.0x10^9/l; leucopenia 1.0-2.0x10^9/l; thrombocytopenia 25-50x10^9/l; severe diarrhea. </td></tr></table><table class=\"table table-striped table-condensed table-hover table-bordered\"><tr><th> Allele Type </th><th> Alleles </th></tr><tr><td> active </td><td> *1, *2, *33, *35 </td></tr><tr><td> decreased activity </td><td> *9, *10, *17, *29, *36, *41  </td></tr><tr><td> inactive </td><td> *3-*8, *11-*16, *19-*21, *38, *40, *42 </td></tr></table><ul><li>*See <a href=\"http://www.pharmgkb.org/home/dutch_pharmacogenetics_working_group.jsp\">Methods</a> or <a href=\"http://www.pharmgkb.org/pmid/18253145\">PMID: 18253145</a> for definition of \"good quality.\"</li><li>S: statistically significant difference.</li></ul>"
}